CLDX Celldex Therapeutics, Inc.
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 744218 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-93.9%
TTM net income YoY-37.6%
TTM EPS YoY-26.9%
Revenue 3-yr CAGR-66.9%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-211,684.8%
Net margin-195,608.9%
FCF margin-164,391.8%
EBITDA margin-209,321.5%
Returns
ROE-49.5%
ROA-45.1%
ROIC (approx.)-44.6%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets10.0%
Debt / equity0.00x
Current ratio10.97x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-8.3%
Payout ratio—
Capex / revenue4,915.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.54M | $7.02M | $6.88M | $2.36M | $4.65M |
| Cost of revenue | $200,000 | $200,000 | $300,000 | $100,000 | $100,000 |
| Gross profit | $1.34M | $6.82M | $6.58M | $2.26M | $4.55M |
| R&D expense | $245.07M | $163.55M | $118.01M | $82.26M | $53.31M |
| SG&A expense | $43.84M | $38.55M | $30.91M | $27.20M | $20.49M |
| Operating income | -$287.37M | -$195.08M | -$154.54M | -$115.23M | -$71.24M |
| Pretax income | -$258.76M | -$157.86M | -$141.43M | -$112.33M | -$70.74M |
| Income tax | $0 | $0 | $0 | — | -$227,000 |
| Net income | -$258.76M | -$157.86M | -$141.43M | -$112.33M | -$70.51M |
| EBITDA | -$283.99M | -$191.90M | -$151.53M | -$112.34M | -$68.17M |
| EPS (basic) | -3.90 | -2.45 | -2.92 | -2.40 | -1.64 |
| EPS (diluted) | -3.90 | -2.45 | -2.92 | -2.40 | -1.64 |
| Weighted avg. shares (diluted) | 66.42M | 64.39M | 48.45M | 46,888 | 42,870 |
| Balance sheet | |||||
| Cash & equivalents | $28.87M | $28.36M | $34.81M | $29.43M | $39.14M |
| Short-term investments | $489.70M | $696.92M | $388.78M | $275.52M | $369.11M |
| Current assets | $534.66M | $747.16M | $431.69M | $317.69M | $410.84M |
| PP&E, net | $5.33M | $4.35M | $4.06M | $3.75M | $3.55M |
| Intangibles | $27.19M | $27.19M | $27.19M | $27.19M | $27.19M |
| Total assets | $582.98M | $792.34M | $465.63M | $352.74M | $444.65M |
| Current liabilities | $50.99M | $39.50M | $31.12M | $18.61M | $16.53M |
| Total liabilities | $55.82M | $45.34M | $36.46M | $26.53M | $25.18M |
| Shareholders' equity | $527.16M | $747.00M | $429.17M | $326.20M | $419.48M |
| Shares outstanding | 66.55M | 66.37M | 55.88M | 47.20M | 46.73M |
| Cash flow statement | |||||
| Operating cash flow | -$210.94M | -$157.78M | -$107.29M | -$103.73M | -$60.91M |
| Capital expenditure | $2.71M | $1.92M | $1.82M | $1.83M | $1.25M |
| Free cash flow | -$213.66M | -$159.70M | -$109.11M | -$105.56M | -$62.16M |
| Investing cash flow | $209.07M | -$290.13M | -$105.78M | $89.94M | -$216.16M |
| Financing cash flow | $2.39M | $441.45M | $218.46M | $4.08M | $272.37M |
| Depreciation & amortization | $3.38M | $3.18M | $3.01M | $2.90M | $3.07M |
| Stock-based compensation | $36.22M | $34.24M | $23.89M | $15.61M | $8.95M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.